Anti-Inflammatory Effects of Red Rice Bran Extract Ameliorate Type I Interferon Production via STING Pathway

Amnart Onsa-Ard 1, Rungthip Thongboontho 1, Narongsuk Munkong 2, Kanokkarn Phromnoi 1, Atcharaporn Ontawong 3, Sirinat Pengnet 3 and Arthid Thim-Uam 1,*

1 Division of Biochemistry, School of Medical Sciences, University of Phayao, Phayao 56000, Thailand; nard27@hotmail.com (A.O.-A.); rungchaos@hotmail.com (R.T.); kanokkarn.ph@up.ac.th (K.P.)
2 Department of Pathology, School of Medicine, University of Phayao, Phayao 56000, Thailand; jittmunkong@gmail.com
3 Division of Physiology, School of Medical Sciences, University of Phayao, Phayao 56000, Thailand; ontawongao@gmail.com (A.O.); nan_1801@hotmail.com (S.P.)
* Correspondence: arthidth@gmail.com

Abstract: Type I interferons (IFNs-I) are inflammatory cytokines that play an essential role in the pathogenesis of inflammation and autoimmune diseases. Signaling through nucleic acid sensors causes the production of IFNs-I. A stimulator of interferon genes (STING) is a DNA sensor that signals transduction, leading to the production of IFNs-I after their activation. This study aims to determine the anti-inflammatory effects of red rice bran extract (RRBE) on macrophages through the activation of STING signaling. RAW264.7 macrophage cells were stimulated with STING agonist (DMXAA) with and without RRBE. Cells and supernatant were collected. The level of mRNA expression was determined by qPCR, and inflammatory cytokine production was investigated by ELISA. The results indicate that RRBE significantly lowers the transcription of STING and interferon-stimulated genes (ISGs). Moreover, RRBE suppresses the phosphorylation of STING, leading to a decrease in the expression of Irf3, a transcription factor that initiates IFN-I signaling. Our results provide evidence that red rice bran extract may be a protective compound for inflammatory diseases by targeting STING signaling.

Keywords: STING; red rice bran; type-I interferon; inflammation

1. Introduction

Inflammation is the essential process for responding to pathogenic infections, cancer, autoimmune diseases, and other inflammatory diseases. Several studies suggest that the regulation of the inflammatory process involves both innate and adaptive immune systems [1–3]. IFNs-I are among the critical cytokines for inflammatory response and consist of IFN-α and IFN-β [4]. After secretion, IFNs-I bind to the type I IFN-α receptor (IFNAR) on target cells that signal downstream through JAK/STAT pathways to enhance the transcription of IFN-stimulated genes (ISGs), which contributes to the inflammatory responses of the body by the different mechanisms [5]. Furthermore, IFNs-I are cytokines that play a role in systemic lupus erythematosus (SLE) and rheumatoid arthritis [6]. These cytokines are mainly produced by plasmacytoid dendritic cells and macrophages [7,8]. Several investigations have indicated that patients with severe SLE express high levels of ISGs in peripheral blood mononuclear cells (PBMCs) [9,10]. In addition, several studies have revealed that activation via nucleic acid–sensor pathways induces IFNs-I production [11–13]. Interestingly, the stimulator of interferon genes (STING) is a cytoplasmic adaptor protein residing in the ER membrane that signals transduction to increase IFNs-I and pro-inflammatory cytokine production [14,15] through cyclic GMP–AMP synthase (cGAS)-mediated cGAMP [16,17]. However, the over-activation of STING in a vascular and pulmonary syndrome (SAVI) promotes the mRNA expression of IFN-β1 and ISGs, including CXCL10 in PBMCs [18].
However, STING-knockout mice induced with pancreatic injury showed less inflammation than STING wild-type mice [19]. Therefore, the inhibition of the STING-mediated pathway involved in inflammation using functional foods could be further investigated for therapeutic opportunities. Bioactive compounds, including flavonoids, proanthocyanidins, and anthocyanins, have been established as having anti-inflammatory and antioxidant effects in several models [20–23]. Among functional food, rice (Oryza sativa L.) is one of the major dietary components in many countries. Several studies report that rice and its bran are an abundant source of bioactive compounds. Moreover, pigmented rice (brown, red, and purple rice) contains various bioactive compounds such as anthocyanins, proanthocyanidins [24], γ-oryzanol, vitamin E [25], tocopherols, and tocotrienols [26], which are concentrated in the bran layer. Interestingly, red rice bran showed the highest effectiveness on the anti-diabetic activity among pigmented rice [24]. Interestingly, rice bran extracts the ameliorative effects of atherosclerosis in high-fat diet (HFD)-induced mice by lowering cholesterol, triglycerides, and oxidized LDL [27]. In addition, the anti-inflammatory activity of proanthocyanidin from red rice extract decreased the production of TNF-α and IL-6 by downregulating the expression of activator proteins-1 (AP-1) and nuclear factor kappa B (NF-Kb) pathways in LPS-stimulated RAW264.7 macrophage cells [28].

Here, we explored the functional role of red rice bran extract as an anti-inflammatory in the activation of STING in RAW264.7 macrophages, and observed this by several in vitro experiments. Furthermore, the phosphorylation of activated STING was also performed. The data from this study provide evidence that STING can be targeted using the extracts from red rice bran for the future treatment of inflammatory diseases.

2. Materials and Methods
2.1. RRBE Preparation

Red rice was obtained from a red glutinous rice variety (Ban Dok Bua, Ban Tun sub-district, Muang Phayao district, Phayao, Thailand). Red rice bran was extracted by 50% ethanol. Briefly, 1 kg of red rice was mixed in 50% ethanol solution (6000 mL) at room temperature for three days. After that, the extracts were filtered through Whatman filter paper number 1 (GE Healthcare UK Ltd., Buckinghamshire, UK) using a vacuum filtration apparatus twice. Then, the samples were concentrated in a rotary evaporator (R-100, BUCHI Labortechnik AG, Flawil, Switzerland). Finally, the extracts were lyophilized to concentrated extracts, and stored at −80 °C prior for further experiments.

2.2. Determination of the Total Flavonoid Content

The total flavonoids from RRBE were examined using the aluminum chloride colorimetric method. Briefly, RRBE (250 µL) was incubated with 75 µL of 5% NaNO₂ for 6 min at RT in the dark. Then, we added 150 µL of 10% aluminum chloride (AlCl₃) and the reaction mixture was incubated for 5 min at RT in the dark. Next, 500 µL of 1 M NaOH and 1525 µL of dH₂O were added to the reaction mixture. The reaction mixtures were determined by a Varioskan Flash microplate reader (Thermo Fisher Scientific, Waltham, MA, USA) at 510 nm. The amount of total flavonoid content from RRBE was calculated using the catechin standard calibration plot and indicated as mg catechin/g extract.

2.3. Determination of the Total Phenolic Content

The total phenolic content from the RRBE was tested using the Folin–Ciocalteu method. Briefly, the RRBE (200 µL) was incubated with 1 mL of 10% Folin–Ciocalteu. Then, we added 800 µL of 7.5% Na₂CO₃ and the reaction mixture was incubated for 15 min at RT in the dark. Next, the absorbance signals were detected with a microplate reader (Thermo Fisher Scientific, Waltham, MA, USA) at 750 nm. The concentration of the total phenolic content from the RRBE was calculated using the gallic acid standard calibration plot and indicated as mg gallic acid/g extract.
2.4. Determination of the Total Proanthocyanidin Content

The total proanthocyanidin content from the RRBE was examined using a vanillin assay. Briefly, the RRBE (40 µL) was incubated with 100 µL of 1% and 100 µL of 9 M sulfuric acid (H2SO4), and the reaction mixture was measured with a Varioskan Flash microplate reader (Thermo Fisher Scientific, Waltham, MA, USA) at 490 nm. The amount of total proanthocyanidin content from the RRBE was calculated using the catechin standard calibration plot and indicated as mg catechin/g extract.

2.5. Cell Culture

RAW 264.7 macrophage cells (1 × 10⁵ cells/mL) were cultured in complete media containing Dulbecco’s modified Eagle’s medium (DMEM) (HyClone, Logan, UT, USA), 10% fetal bovine serum (FBS) (Gibco–Thermo Fisher Scientific, Waltham, MA, USA), 1X anti-antibiotics (Gibco–Thermo Fisher Scientific, MA, USA) and maintained at 37 °C with 5% CO₂. RAW264.7 cells were pretreated with RRBE for 1 h followed by adding 10 µg/mL of STING agonist or DMXAA (5,6-Dimethylxanthone-4-acetic acid) (InvivoGen, San Diego, CA, USA) for 24 h. DMSO (vehicle)-treated cells were used as the control for all subsequent in vitro experiments.

2.6. Determination of Cell Viability by the MTS Assay

RAW 264.7 macrophage cells (1 × 10⁵ cells/mL) were cultured in complete media as described above and maintained at 37 °C with 5% CO₂. The cytotoxicity of the RRBE in macrophages was investigated by the MTS assay following the manufacturer’s instructions (Promega, cat. G3580, Madison, WI, USA). Briefly, macrophages were stimulated with the different doses of the RRBE for 24 h. Then, cells were washed twice with media and 20 µL of MTS reagents was added into each sample in 100 µL of the culture medium. After incubation for 3 h at 37 °C with 5% CO₂, the absorbance signals were measured at 490 nm using a Varioskan Flash microplate reader (Thermo Fisher Scientific, Waltham, MA, USA). Untreated cells were used as the control.

2.7. Determination of Luciferase Activity

RAW-Lucia™ ISG cells (InvivoGen, San Diego, CA, USA) were cultured in complete media supplement with 100 mg/mL of Zeocin (Invitrogen, CA, USA) and 50 mg/mL of Normocin (InvivoGen, San Diego, CA, USA) and maintained at 37 °C with a 5% CO₂ incubator. Cells were treated with different doses of RRBE with and without DMXAA (10 µg/mL) for 24 h. The luciferase activity was monitored in the supernatant using the QUANTI-Luc luciferase reagent detector (InvivoGen, San Diego, CA, USA) per the manufacturer’s instructions.

2.8. Determination of Mature Phenotypes Using Flow Cytometry

RAW 264.7 cells from all experiments (1 × 10⁵ cells) were stained with I-Ab (clone: AF6-120.1; cat. 116406) antibody, and F4/80 (clone: BM8) antibody (Bio Legend, San Diego, CA, USA). Viable cells were stained with fixable Viability Dye eFluor™ 780 (Thermo Fisher Scientific, MA USA). The immune phenotype was performed using a BD™ LSR-II flow cytometer (BD Biosciences, North Brunswick, NJ, USA) and analyzed by FlowJo software (version 10, USA).

2.9. mRNA Expression Analysis

The total RNA was extracted by the TRIzol reagent (Thermo-InvitroGen, Waltham, MA, USA), and RNA was purified by the RNeasy mini kit (QIAGEN, Germantown, MD, USA) as per the manufacturer’s instructions. The total RNA (1 µg) was used for cDNA synthesis using iScript RT Supermix (Bio-Rad, Hercules, CA, USA). The levels of mRNA were tested by real-time PCR using SsoAdvanced Universal SYBR Green Supermix (Bio-Rad, Hercules, CA, USA) using an Applied Biosystems 7500 Real-Time PCR (Applied Biosystems). The relative amounts of target mRNA were normalized by β-actin mRNA as
the housekeeping gene and determined by the 2^{(-\Delta \Delta Ct)} method. A list of primers for the PCR included:

\[ \begin{align*}
\text{Cxcl10} & : \text{F: 5'}-\text{CAGTGAGAATGAGGGCCATAGG-3'} \\
& \text{R: 5'}-\text{CGGATTCAGACATCTCTGCTCA-3'} \\
\text{Mx1} & : \text{F: 5'}-\text{GATCCGACTTCACTTCCAGATGG-3'} \\
& \text{R: 5'}-\text{CATCTCAGTGATGTCACCCAC-3'} \\
\text{Mx1} & : \text{F: 5'}-\text{GATCCGACTTCACTTCCAGATGG-3'} \\
& \text{R: 5'}-\text{CATCTCAGTGATGTCACCCAC-3'} \\
\text{IRF3} & : \text{F: 5'}-\text{GCTTGTGATGGTCAAGGTTGT-3'} \\
& \text{R: 5'}-\text{AGATGTGCAAGTCCACGGTT-3'} \\
\text{IRF5} & : \text{F: 5'}-\text{TTTGAGATCTTCTTTTGCTTTGGA-3'} \\
& \text{R: 5'}-\text{GTACCACCTGTACAGTAATGAGCTCTT-3'} \\
\text{IRF7} & : \text{F: 5'}-\text{CCCAGACTGCCTGTGTAGACG-3'} \\
& \text{R: 5'}-\text{CCAGTCTCCAAACAGCACTCG-3'} \\
\text{IFN-}\beta & : \text{F: 5'}-\text{ATGAGTGGTGGTTGCAGGC-3'} \\
& \text{R: 5'}-\text{TGACCTTTCAAATGCAGTAGATTCA-3'} \\
\text{IFN-}\gamma & : \text{F: 5'}-\text{TTGCCAAGTTTGAGGTCAACAA-3'} \\
& \text{R: 5'}-\text{TGGTGGACCACTCGGATGA-3'} \\
\text{IFN-}\alpha & : \text{F: 5'}-\text{TCTGATGCAGCAGGTGGG-3'} \\
& \text{R: 5'}-\text{AGGGCTCTCCAGACTTCTG-3'} \\
\text{Sting} & : \text{F: 5'}-\text{TGCCGGACACTTGAGGAAAT-3'} \\
& \text{R: 5'}-\text{GTTCGCCGTCTGTGGGTTCTTG-3'}
\end{align*} \]

2.10. Determination of Cytokine Production

RAW 264.7 cells (1 \times 10^5 cells/mL) were cultured, then the RRBE was treated with and without DMXAA activation for 24 h. The supernatant was collected, and the concentrations of IFN-\gamma and IL-10 were measured by ELISA using the IFN-\gamma Mouse Uncoated ELISA Kit (cat. 88-7314-88) and the IL-10 Mouse Uncoated ELISA Kit (cat. 88-7105) (Thermo Fisher Scientific, Waltham, MA, USA) according to the manufacturer’s instructions. The absorbance signals were detected using a Varioskan Flash microplate reader (Thermo Fisher Scientific, Waltham, MA, USA).

2.11. Determination of Nitric Oxide (NO) Production

The levels of NO were tested using a Griess reagent assay. Briefly, RAW264.7 cells (1 \times 10^5 cells/mL) were cultured in complete medium and stimulated by DMXAA with and without RRBE for 24 h. The supernatant was collected and 100 \mu L of supernatant was incubated with 100 \mu L of Griess reagents at room temperature for 10 min. The absorbance signals were measured at 540 nm using a Varioskan Flash microplate reader (Thermo Fisher Scientific, Waltham, MA, USA). Untreated cells were used as the control.

2.12. Immunofluorescence

RAW 264.7 cells (1 \times 10^5 cells/mL) were cultured, then underwent DMXAA treatment with and without RRBE for 3 h. After that, fixed cells were performed at room temperature for 10 min by 4% formalin (Sigma-Aldrich, Darmstadt, Germany). The fixed cells were stained with 0.2% Triton X-100 for 10 min at room temperature and blocked the unspecific binding of the antibodies with 1% BSA for 1 h. Cells were stained with STING antibody (clone: D2P2F cat: 13647, 1:200) (Cell Signaling, Danvers, MA, USA) at 4 \degree C. Then, the secondary antibody Alexa Fluor 488 rabbit IgG (Thermo Fisher Scientific, Waltham, MA, USA) was added for 1 h at room temperature. Next, cells were stained with 1 \mu M DAPI (Thermo Fisher Scientific, Waltham, MA, USA) for 5 min in the dark and the fluorescence was visualized with a confocal microscope (Carl Zeiss LMS800, Oberkochen, Germany).

2.13. Determination of STING by Western Blot

RAW 264.7 cells (1 \times 10^6 cells) were cultured, then underwent DMXAA treatment with and without RRBE for 3 h. Cells were lysed in buffer C (final concentration at 150 mM of NaCl, 5 mM of EDTA pH 8, 1% of Triton-X100 and 10 mM of Tris-HCl pH 7.4). Protein
Lysates were homogenized and centrifuged at 12,000× g, 15 min at 4 °C. The proteins were collected in the supernatants. Then, total protein was examined with a BCA assay (Thermo Fisher Scientific, Waltham, MA, USA). Next, 15 μg of total protein was boiled in Laemmli buffer at 95 °C for 5 min. The equal proteins were separated on a 12.5% SDS-polyacrylamide gel. Then, nitrocellulose membranes were used for transferring the proteins and blocking the unspecific binding of the antibodies with 5% BSA for 1 h. The membranes were probed with STING antibody (clone: D2P2F cat: 13647, 1:2000) (Cell Signaling, Danvers, MA, USA) and incubated at 4 °C overnight. The membranes were washed with wash buffer and probed with the fluorescent secondary antibody IRDye® 680RD donkey anti-rabbit IgG (1:10,000) (LI-COR, Lincoln, NE, USA) at room temperature for 1 h. Membranes were determined by protein signals using ODYSSEY CLx (LI-COR, Lincoln, NE, USA).

2.14. In-Gel Digestion and Identification of Protein by Mass Spectrometry

The equal protein from cell lysates was separated on a 12.5% SDS-polyacrylamide gel. Then, the protein in gel was cut into small pieces (~0.5–1 mm³). A small gel particle size facilitates the removal of SDS and coomassie by 25 mM NH₂HCO₃. Next, protein in gels was reduced and alkylated by dithiothreitol (DTT) for 30 min at 37 °C and iodoacetamide (IA) (Sigma-Aldrich, Darmstadt, Germany) for 30 min at room temperature in the dark, respectively. These samples were further quenched with DTT for 15 min at room temperature before incubating with trypsin at a ratio of 1:50 at 37 °C for 16 h. After digestion, tryptic proteins were extracted from the gels by adding 30 μL of 50% CH₃CN/1% trifluoroacetic acid (TFA). Next, the peptides from the supernatant were removed and collected in a clean LoBind tube and the extracts were concentrated on speedvac. Finally, these digested proteins were resuspended in 0.1% formic acid and subjected to LC-MS/MS (Thermo Scientific, Waltham, MA, USA). The data from mass spectrometry were analyzed by Proteome Discoverer version 2.1 software (Thermo Scientific, Waltham, MA, USA).

2.15. Statistical Analysis

All statistical analyses between groups were conducted using a two-tailed Mann-Whitney test, and multiple group comparisons were performed using one-way ANOVA. The standard error of mean (SEM) was used for data presentation. Statistical analyses were performed using GraphPad Prism 8.0 (GraphPad Software, San Diego, CA, USA). A p-value of <0.05 was considered statistically significant.

3. Results

3.1. Bioactive Contents of Rrice Bran Extract (RRBE)

The bioactive compounds from RRBE were determined using colorimetric methods. The results showed that red rice bran extract contains an essential bioactive compound, with a total phenolic content of 51.9 ± 1.73 mg of GAE/g, total flavonoid content of 22.94 ± 2.62 mg of catechin/g, and total proanthocyanidin content of 6.52 ± 0.90 mg of catechin/g as shown in Table 1. Because the bioactive contents were identified, these extracts could be observed during anti-inflammatory activity.

Table 1. Bioactive compounds of RRBE.

| Bioactive                        | Constituents  |
|---------------------------------|--------------|
| Total phenolic content (mg GAE/g)| 51.9 ± 1.73  |
| Total flavonoid content (mg Catechin/g) | 22.94 ± 2.62 |
| Proanthocyanidins (mg Catechin/g) | 6.52 ± 0.90  |

The red rice bran was extracted by 50% ethanol and we determined the essential compounds using colorimetric methods. Data shown as means ± SD (n = 3).

3.2. Effects of RRBE on Cytotoxicity and the Production of Inflammatory Cytokines

An MTS assay was used to determine the cytotoxicity of the different doses of RRBE for 24 h on RAW 264.7 macrophage cells. The results showed that cell viabilities were not
significantly affected between 100 and 3000 µg/mL of RRBE compared with the control (Figure 1A). Next, we used the different concentrations of RRBE to examine the anti-inflammatory cytokine production using STING agonist (DMXAA) activation. A previous study indicated that the appropriate concentration of DMXAA was 10 µg/mL [29]. We found that RRBE significantly decreases the levels of luciferase in the culture medium of activated RAW-Lucia™ ISG cells that were secreted under the control of interferon regulatory factor 3 (IRF3)-inducible Lucia luciferase and type I IFN production at a concentration of 2 mg/mL (Figure 1B). We used this concentration for all subsequent in vitro experiments.

![Figure 1. Effects of RRBE on the cytotoxicity and production of inflammatory cytokines. (A) The cytotoxic effects of different concentrations of RRBE were examined in comparison with the untreated group by an MTS assay (N = 3–4). (B) The levels of luciferase in the culture medium were determined by a luciferase detection reagent after DMXAA activation with and without RRBE for 24 h in RAW-Lucia™ ISG cells (N = 3–6). Data shown as mean ± SEM, ** p < 0.01, and *** p < 0.001.

3.3. Effects of RRBE on the Activation of RAW 264.7 Macrophage Cells

We determined the activation of macrophage cells using flow cytometry after DMXAA activation with and without RRBE. RAW 264.7 macrophage cells were co-stained with F4/80, a surface marker identifying the mouse macrophages, and an I-Ab marker determining the activation of mouse macrophages. The treatment of macrophages with DMXAA alone showed a significant increase in the I-Ab alloantigen (MHC class II molecules), indicating fluorescent intensity, which was highly expressed on antigen-presenting cells. These surface molecules indicated macrophages activation. In comparison, the MHC-II molecules diminished in the presence of RRBE (Figure 2A–C). Moreover, we confirmed the morphology using imaging flow cytometry. The results showed that the macrophages decreased the expression of MHC-II molecules by RRBE (Figure 2D). Additionally, cell viability was tested (Figure 2E). These data suggested that RRBE diminishes the activation of RAW246.7 macrophages after the stimulation of the STING agonist by decreasing the expression of MHC-II molecules.
Moreover, the stimulation of the STING agonist by deoxyribonucleic acid (DNA) with and without RRBE for 24 h (N = 3–4). (Figure 4A,B), while the mRNA levels of Ifn-β were upregulated after DMXAA stimulation and downregulated by RRBE treatment (Figure 3D). In addition, activation through the STING pathway enhances IFNs-I. Then, these cytokines initiate IFN-γ and nitric oxide (NO) production in activated macrophages [31]. Our study at 24 h showed that the secretion of IFN-γ and nitric oxide (NO) from DMXAA activation in the culture medium significantly increased the expression of MHC-II molecules (I-Ab), and subsequently determined by a flow cytometer. (Figure 4A,B,C,D,E). Error bar shown as mean ± SEM (* p < 0.05 and *** p < 0.001).

3.4. Anti-Inflammatory Effect of RRBE on RAW 264.7 Cells via STING Signaling

Next, the anti-inflammatory effects of RRBE via the STING pathway were investigated. The cells and supernatant were collected after the activation of DMXAA with and without RRBE. DMXAA induced the production of luciferase activity that showed the inflammatory process through type I interferon signaling. However, this induction was significantly decreased by the addition of RRBE at 3, 6, and 24 h (Figure 3A). Moreover, the mRNA levels of interferon-inducible genes (Ifn-α, Irf3, Irf5, Irf7, and Mx1) at 3 h were upregulated after DMXAA stimulation and downregulated by RRBE treatment (Figure 3B–G). Nevertheless, Cxcl10 did not alter DMXAA with RRBE treatment (Figure 3D). In addition, activation through the STING pathway enhances IFNs-I. Then, these cytokines initiate IFN-γ secretion [30], which increases the expression of iNOS and leads to nitric oxide (NO) production in activated macrophages [31]. Our study at 24 h showed that the secretion of IFN-γ and nitric oxide (NO) from DMXAA activation in the culture medium significantly increased (Figure 4A,B), while the mRNA levels of Ifn-γ, Ifn-α, and Ifn-β were downregulated in the presence of RRBE (Figure 4C–E). This finding suggested that RRBE decreased inflammatory responses through the STING-dependent pathway.
Figure 3. Effects of RRBE on the interferon-inducible gene expression. (A) The luminescence activity through STING signaling was determined after DMXAA activation with and without RRBE for 3, 6 and 24 h (N = 3–5). The relative mRNA expressions (normalized by actin) of (B) Ifn-α, (C) Mx1, (D) Cxcl10, (E) Irf3, (F) Irf5 and (G) Irf7 after DMXAA stimulation with and without RRBE for 3 h (N = 3–4) are shown. Error bars indicate SEM, * p < 0.05, ** p < 0.01, and *** p < 0.001.
Figure 4. Effects of RRBE on the production of IFN-γ and nitric oxide. (A) Supernatants were collected, and we determined the concentration of IFN-γ after DMXAA with and without RRBE for 24 h by ELISA (N = 4–7). (B) Nitric oxide (NO) production was determined by the Griess assay (N = 7 to 10 per group). The mRNA expression (normalized by actin) of (C) Ifn-γ, (D) Ifn-α and (E) Ifn-β are shown. Data are shown as mean ± SEM, *p < 0.05, and ***p < 0.001.

3.5. Effect of RRBE in the Activated Macrophages Decreases the Phosphorylation of STING

To better understand the effect of RRBE on the STING-mediated pathway, our previous data found that STING plays a function role after being activated for 3 h [29]. Therefore, we performed the mRNA expression of Sting by real-time PCR in RAW 264.7 cells after treatment by DMXAA with and without RRBE at this time point. The expression of Sting was upregulated in the DMXAA activation compared with the presence of RRBE (Figure 5A). Additionally, we demonstrated the Western blot analysis. We found that RRBE treatment decreased the upper band of STING. This upper band, identified by mass spectrometry (LC-MS/MS)), was the phosphorylation of STING at Ser357 (data not shown) (Figure 5B). Next, we confirmed the activation of STING by confocal microscopy. These results found a higher expression of STING in DMXAA stimulation and a significant reduction in the presence of RRBE (Figure 5C). Moreover, the fluorescence intensity of the activated STING showed a significant increase in the presence of DMXAA, whereas there was a decrease in the RRBE treatment (Figure 5D). Our data suggested that the activated STING diminished in the presence of RRBE.
3.6. RRBE Promotes the Anti-Inflammatory Production of IL-10 in Macrophages

Next, we investigated the anti-inflammatory activity of RRBE. The secretion of IL-10 from the supernatant was measured by ELISA. The results showed a significantly increased IL-10 production from the RRBE treatment with DMXAA compared to the DMXAA alone (Figure 6A,C). Furthermore, we further looked at the gene expressions and found they were significantly upregulated after treatment with RRBE (Figure 6B,D). These data suggested that RRBE enhances the mRNA expression and secretion of IL-10.
The current study provides evidence for the possible anti-inflammatory effect of RRBE through the STING-mediated pathway in macrophage cells. The STING signaling pathway contributes to both the innate and adaptive immune systems. Several studies report the regulatory function of STING in autoimmune diseases, cancers, and inflammatory diseases [15,32,33]. Here, we detected the bioactive compounds, including total phenolic, total flavonoid, and proanthocyanidin content (Table 1). These data demonstrated that 50% ethanol extract of red rice bran contains various essential bioactive compounds similar to other colored rice extracts [34,35], showing antioxidant activity and an anti-inflammatory effect [36–38]. According to previous results [25,39], 40–70% ethanol extract had high total phenolic content (TPC) and exerted in vitro antioxidant and anti-inflammatory activities. Moreover, 50% ethanol fraction from red rice, which contains phenolics, proanthocyanins, and other phytochemicals, significantly increased glucose uptake in adipocytes and decreased inflammatory markers in macrophages [24,28]. In line with this, our preliminary study showed that the 50% ethanol extract of red rice bran had higher TPC compared with white rice bran and water extract (data not shown), but its TPC was not significantly different with 70% ethanol extract. Moreover, a previous study indicated that rice bran phenolic extracts decrease pro-inflammatory cytokines including monocyte chemoattractant protein 1 (MCP-1), tumor necrosis factor-α (TNF-α), interleukin-12, p70 (IL-12p70), and interferon-γ (IFN-γ) by the synergistic action of the bioactive compounds in the rice bran extract [40,41]. These results suggested that the anti-inflammatory effects observed could be due to the combination of bioactive compounds identified in red rice bran extract.

STING agonist (DMXAA)-stimulated RAW264.7 cells exhibit an increased expression of I-Ab (MHC-II) molecules, indicating the activation of macrophages into antigen-presenting cells [42]. The mature phenotype of activated macrophage cells was reduced in the presence of RRBE (Figure 2). Next, we observed the effects of RRBE decreasing the secretion of IFN-γ and nitric oxide in the culture medium after DMXAA-activated cells (Figure 4). Additionally, RRBE reduced the interferon-inducible genes (Irf3, Irf5, Irf7 and Mx1) (Ifn-γ, Ifn-β, and Ifn-a) (Figures 3 and 4). The increase in IFN-γ might be due to the
phosphorylation of STAT4 through IFNs-I signaling (Figure 7) [7,43]. On the other hand, Cxcl10, which is a chemokine, did not decrease in the initial stimulation, but this gene was downregulated at 24 h after treatment (data not shown). This data may result from the decrease in IFN-γ secretion and type 1 IFNs (IFN-α and IFN-β) in the supernatant, which can turn on the expression of Cxcl10 via activating the JAK/STAT pathway [44–46]. Moreover, the secretion of IFN-γ (after binding their receptors) can initiate the transcription of inducible nitric oxide synthase (iNOS) in activated macrophages [47] through the induced tyrosine phosphorylation of STAT1 signaling [48], and promote the production of NO (Figure 4B) [31,49,50]. These data suggested that RRBE reduced the IFN-γ and nitric oxide was STING-dependent.

**Figure 7.** Schematic illustrations of RRBE’s effects via the STING-mediated pathway. RRBE ameliorates IFN-I production through decreasing the phosphorylation of STING. This figure was created by Biorender.com.

This intriguing effect of RRBE via STING signaling in the inflammatory response was demonstrated. Our results showed that RRBE exhibited the anti-inflammatory effects through IFN-I signaling by lowering the mRNA expression of Sting (Figure 5A). However, we found that the total abundant protein of STING was not altered (Figure 5B). Interestingly, we detected the upper band of the STING increase in the DMXAA-treated cells and a decrease in the RRBE treatment (Figure 5B) using the total STING antibody (clone D2P2F, which recognized the STING at the C-terminal). Our previous data consistency with this result showed that this upper band, identified by mass spectrometry (LC-MS/MS), was the phosphorylation of STING at Ser357 (data not shown) [29], a homolog with S358 in human STING [51]. Subsequently, phosphorylated S357 of STING at the C-terminal (CTT, 343–379) is essential for the recruitment and phosphorylation of the downstream TANK-binding kinase 1 (TBK1) [52]. The steady state of STING resides in the ER membrane. After activation, STING trafficked to Golgi, in which the post-translational modification (PTMs) occurs for recruiting and activating TBK1. The activation, protein localization, and protein–protein interactions of STING are also regulated by several PTM processes, including ubiquitylation, SUMOylation, phosphorylation, and palmitoylation [52,53]. The data from this result assume that the Western blot from cell lysate showed another upper
band of STING after the DMXAA activation could be due to the several PTMs processes. In addition, we found the RRBE treatment reduced the expression of STING by immunofluorescence staining using the STING-C antibody (Figure 5C,D). These data may result from the detection of total abundant and phosphorylated STING protein at the C-terminal. Afterward, the pSTING–pTBK1 complex activates IRF3, which is phosphorylated by TBK1. The phosphorylated IRF3 (pIRF3) dimerizes and translocates into the nucleus, initiating IFNs-I gene expression [54]. Therefore, this activation enhances IFNs-I production and other pro-inflammatory cytokines [55–58].

In this work, we found STING phosphorylation was suppressed by RRBE, which led to the lower Irf3 expression (Figure 3E). IRF3 is the transcription factor that requires signaling through the STING-mediated pathway [54,59,60]. Our data suggested that the mRNA expression of Irf3 in RRBE-treated macrophage cells was STING-dependent (Figure 7). These findings suggested that RRBE might affect STING function by suppressing phosphorylation, which leads to their reduced transcription downstream (Figure 7).

Previous studies revealed that proanthocyanidin-rich red rice extract decreased the pro-inflammatory cytokines, including TNF-α and IL-6, in activated macrophages by down-regulating the expression of NF-Kb pathways [28]. In this work, the bioactive compounds obtained from RRBE (Table 1) showed the anti-inflammatory effects of IFNs-I production through the suppressed phosphorylation of STING. These effects lead to the down-regulation of phosphorylated TBK1, which can promote the translocation of pIRF3 to the nucleus. Moreover, pTBK1 can promote NF-Kb signaling and initiate the transcription of pro-inflammatory cytokines. These findings suggested that the reduced inflammation of RRBE was STING-dependent and independent signaling.

Furthermore, we observed the level of IL-10 production in the culture medium; this is a major immunosuppressive cytokine that plays a crucial role in preventing inflammatory and autoimmune diseases [61]. We found the treatment of RRBE enhanced the production of IL-10 in DMXAA-stimulated macrophage cells (Figure 6). Enhanced IL-10 in the culture medium of RRBE-treated cells was due to higher IL-10 mRNA expression (Figure 6). A previous study showed that IFN-I through the STING-mediated pathway promotes the level of IL-10 [62,63]. In contrast, the activation of bone marrow-derived macrophages (BMDM) via cGAS-STING signaling in an allergic encephalomyelitis (EAE) mouse model showed IL-10 production without requiring IFN-I [64]. Therefore, IL-10 production can also occur through several pathways, including TLR signaling, IFN-I, and nuclear factor kB (NF-kB) [65]. Therefore, our results suggested that the increased production of IL-10 by RRBE may be STING-independent signaling. These data proposed that RRBE decreased the activated RAW264.7 macrophages’ phenotypes by reducing the production of IFNs, and this was STING-dependent.

5. Conclusions

This work aims to preliminarily study the anti-inflammatory effects of RRBE via the STING pathway to target a functional food component, which combines a variety of bioactive compounds. Our results indicate that the IFN-I produced via STING-mediated signaling was decreased by 2 mg/mL of RRBE treatment, and this concentration was not affected by cytotoxicity in the macrophages. We found that RRBE decreases the phosphorylation of STING, leading to a reduction in the transcription of Irf3, a transcription factor that initiates IFNs-I signaling. Additionally, these effects decrease the expression of interferon-inducible genes (If-γ, If-β, If-α, and Mx1). Moreover, the inflammatory cytokines, IFN-γ, and NO production diminished in the presence of RRBE. In addition, we found that the treatment of RRBE enhanced the production of immunosuppressive cytokine, IL-10. A further study via in vivo experiments to evaluate the bioactivity of RRBE for treatment involved in inflammatory disease was carried out. Therefore, blocking the STING pathway may improve inflammation, and it would probably be worthwhile to develop a therapeutic drug target using bioactive compounds from red rice bran extracts.
Author Contributions: Conceptualization, A.T.-U. and A.O.-A.; methodology, A.T.-U., A.O.-A., R.T., N.M., K.P., A.O. and S.P.; validation, A.T.-U., A.O.-A. and R.T.; formal analysis, A.T.-U., A.O.-A., R.T. and N.M.; investigation, A.T.-U.; resources, A.T.-U.; data curation, A.T.-U., A.O.-A., R.T. and N.M.; writing—original draft preparation, A.T.-U.; writing—review and editing, A.T.-U.; visualization, A.T.-U.; supervision, A.T.-U.; project administration, A.T.-U.; funding acquisition, A.T.-U. and K.P. All authors have read and agreed to the published version of the manuscript.

Funding: (A.T.-u.) This research was funded by the Thailand Science Research and Innovation Fund and the University of Phayao, Grant No. FF64-UoE020 and FF64-RIB008 and the School of Medical Sciences, Grant No. MS201006. K.P. was supported by the Thailand Science Research and Innovation Fund and the University of Phayao, Grant No. UoE65005. S.P. was supported by the Thailand Science Research and Innovation Fund and the University of Phayao, Grant No. FF64-RIM039.

Data Availability Statement: Data is contained within the article.

Acknowledgments: This research was funded by the Thailand Science Research and Innovation Fund and the University of Phayao, for A.T.-U. Grant No. FF64-UoE020 and FF64-RIB008 and School of Medical Sciences, Grant No. MS201006, for K.P. Grant No. UoE65005, for K.P. Grant No. FF64-RIM039.

Conflicts of Interest: The authors declare no conflict of interest.

References
1. Arulselvan, P.; Fard, M.T.; Tan, W.S.; Gothai, S.; Fakurazi, S.; Norhaizan, M.E.; Kumar, S.S. Role of antioxidants and natural products in inflammation. *Oxidative Med. Cell. Longev.* 2016, 2016, 5276130. [CrossRef]
2. Cronkite, D.A.; Strutt, T.M. The regulation of inflammation by innate and adaptive lymphocytes. *J. Immunol. Res.* 2018, 2018, 1467538. [CrossRef]
3. Vincenzo, B.; Asif, I.J.; Nikolaos, P.; Francesco, M. Adaptive Immunity and Inflammation. *Int. J. Inflamm.* 2015, 2015, 575406. [CrossRef]
4. Kopitar-Jerala, N. The Role of Interferons in Inflammation and Inflammasome Activation. *Front. Immunol.* 2017, 8, 873. [CrossRef]
5. Chen, K.; Liu, J.; Cao, X. Regulation of type I interferon signaling in immunity and inflammation: A comprehensive review. *J. Autoimmun.* 2017, 83, 1–11. [CrossRef]
6. Muskardin, T.L.W.; Niewold, T.B. Type I interferon in rheumatic diseases. *Nat. Rev. Rheumatol.* 2018, 14, 214–228. [CrossRef]
7. McNab, F.; Mayer-Barber, K.; Sher, A.; Wack, A.; O’Garra, A. Type I interferons in infectious disease. *Nat. Rev. Immunol.* 2015, 15, 87–103. [CrossRef]
8. Fitzgerald-Bocarsly, P.; Feng, D. The role of type I interferon production by dendritic cells in host defense. *Biochimie* 2007, 89, 843–855. [CrossRef]
9. Psarras, A.; Emery, P.; Vital, E.M. Type I interferon–mediated autoimmune diseases: Pathogenesis, diagnosis and targeted therapy. *Rheumatology* 2017, 56, 1662–1675. [CrossRef]
10. Baechler, E.C.; Batiwalla, F.M.; Karypis, G.; Gaffney, P.M.; Espe, K.J.; Shark, K.B.; Grande, W.J.; Hughes, K.M.; Kapur, V. Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus. *Proc. Natl. Acad. Sci. USA* 2003, 100, 2610–2615. [CrossRef]
11. Paludan Søren, R. Activation and Regulation of DNA-Driven Immune Responses. *Microbiol. Mol. Biol. Rev.* 2015, 79, 225–241. [CrossRef]
12. Shrivastav, M.; Niewold, T. Nucleic Acid Sensors and Type I Interferon Production in Systemic Lupus Erythematosus. *Front. Immunol.* 2013, 4, 319. [CrossRef]
13. Cai, C.; Tang, Y.-D.; Xu, G.; Zheng, C. The crosstalk between viral RNA and DNA-sensing mechanisms. *Cell. Mol. Life Sci.* 2021, 78, 7427–7434. [CrossRef]
14. Barber, G.N. STING: Infection, inflammation and cancer. *Nat. Rev. Immunol.* 2015, 15, 760–770. [CrossRef]
15. Burdette, D.L.; Vance, R.E. STING and the innate immune response to nucleic acids in the cytosol. *Nat. Immunol.* 2013, 14, 19–26. [CrossRef]
16. Ablasser, A.; Goldeck, M.; Cavlar, T.; Deimling, T.; Witte, G.; Röhler, I.; Hopfner, K.-P.; Ludwig, J.; Hornung, V. cGAS produces a 2′-5′-linked cyclic dinucleotide second messenger that activates STING. *Nature* 2013, 498, 380–384. [CrossRef]
17. Kato, K.; Omura, H.; Ishitani, R.; Nureki, O. Cyclic GMP–AMP as an endogenous second messenger in innate immune signaling by cytosolic DNA. *Annu. Rev. Biochem.* 2017, 86, 541–566. [CrossRef]
18. Liu, Y.; Jesus, A.A.; Marrero, B.; Yang, D.; Ramsey, S.E.; Montealegre Sanchez, G.A.; Tenbrock, K.; Wittkowski, H.; Jones, O.Y.; Kuehn, H.S. Activated STING in a vascular and pulmonary syndrome. *N. Engl. J. Med.* 2014, 371, 507–518. [CrossRef]
19. Zhao, Q.; Wei, Y.; Pandol, S.J.; Li, L.; Habtezion, A. STING Signaling Promotes Inflammation in Experimental Acute Pancreatitis. *Gastroenterology* 2018, 154, 1822–1835.e2. [CrossRef]
20. Baiges, I.; Palmfeldt, J.; Blade, C.; Gregersen, N.; Arola, L. Lipogenesis is decreased by grape seed proanthocyanidins according to liver proteomics of rats fed a high fat diet. *Mol. Cell. Proteom.* 2010, 9, 1499–1513. [CrossRef]
11. Karlsen, A.; Retterstol, L.; Laake, P.; Paur, I.; Kjolsrud-Bohn, S.; Sandvik, L.; Blomhoff, R. Anthocyanins inhibit nuclear factor-κB activation in monocytes and reduce plasma concentrations of pro-inflammatory mediators in healthy adults. *J. Nutr.* 2007, 137, 1951–1954. [CrossRef]

12. Zhang, Z.; Li, Y.; Li, Y. Grape seed proanthocyanidin extracts prevent hyperglycemia-induced monocyte adhesion to aortic endothelial cells and ameliorates vascular inflammation in high-carbohydrate/high-fat diet and streptozotocin-induced diabetic rats. *Int. J. Food Sci. Nutr.* 2016, 67, 524–534. [CrossRef]

13. Aboonabi, A.; Aboonabi, A. Anthocyanins reduce inflammation and improve glucose and lipid metabolism associated with inhibiting nuclear factor-kappaB activation and increasing PPAR-γ gene expression in metabolic syndrome subjects. *Free Radic. Biol. Med.* 2020, 150, 30–39. [CrossRef]

14. Boue, S.M.; Daigle, K.W.; Chen, M.-H.; Cao, H.; Heiman, M.L. Antidiabetic Potential of Purple and Red Rice (*Oryza sativa* L.) Bran Extracts. *J. Agric. Food Chem.* 2016, 64, 5345–5353. [CrossRef]

15. Surarit, W.; Jansom, C.; Lerdvuthisopon, N.; Kongkham, S.; Hansakul, P. Evaluation of antioxidant activities and phenolic subtype contents of ethanolic bran extracts of Thai pigmented rice varieties through chemical and cellular assays. *Int. J. Food Sci. Technol.* 2015, 50, 990–998. [CrossRef]

16. Huang, Y.-P.; Lai, H.-M. Bioactive compounds and antioxidative activity of colored rice bran. *J. Food Drug Anal.* 2016, 24, 564–574. [CrossRef]

17. Tan, X.W.; Kobayashi, K.; Shen, L.; Inagaki, J.; Ide, M.; Hwang, S.S.; Matsuura, E. Antioxidative attributes of rice bran extracts in ameliorative effects of atherosclerosis-associated risk factors. *Heiyou 2020*, 6, e05743. [CrossRef]

18. Limtrakul, P.; Yodkeeree, S.; Pitchakarn, P.; Punfa, W. Anti-inflammatory effects of proanthocyanidin-rich red rice extract via suppression of MAPK, AP-1 and NF-κB pathways in RAW 264.7 macrophages. *Nutr. Res. Pract.* 2016, 10, 251–258. [CrossRef]

19. Thim-Uam, A.; Prabakaran, T.; Tansakul, M.; Makjaroen, J.; Wongkongkathep, P.; Chantaravisoot, N.; Saethang, T.; Leelaha-vanchikul, A.; Benjachat, T.; Paludan, S.R. STING mediates lupus via the activation of conventional dendritic cell maturation and plasmacytoid dendritic cell differentiation. *Isisience 2020*, 23, 101530. [CrossRef]

20. Papinska, J.; Bagavant, H.; Gymsrek, G.B.; Sroka, M.; Tummala, S.; Fitzgerald, K.A.; Deshmukh, U.S. Activation of Stimulator of Interferon Genes (STING) and Sjögren Syndrome. *J. Dent. Res.* 2018, 97, 893–900. [CrossRef]

21. Xiong, H.; Xi, Y.; Yuan, Z.; Wang, B.; Hu, S.; Fang, C.; Cai, Y.; Fu, X.; Li, L. IFN-γ activates the tumor cell-intrinsic STING pathway through the induction of DNA damage and cytosolic dsDNA formation. *OncoImmunology 2022*, 11, 2044103. [CrossRef]

22. Decout, A.; Katz, J.D.; Venkatraman, S.; Ablasser, A. The cGAS–STING pathway as a therapeutic target in inflammatory diseases. *Nat. Rev. Immunol.* 2021, 21, 548–569. [CrossRef]

23. Couillin, I.; Riteau, N. STING Signaling and Sterile Inflammation. *Front. Immunol.* 2021, 12, 753789. [CrossRef]

24. Ghasemzadeh, A.; Karbalaii, M.T.; Jaafar, H.Z.E.; Rahmat, A. Phytochemical constituents, antioxidant activity, and antiproliferative properties of black, red, and brown rice bran. *Chem. Cent. J.* 2018, 12, 17. [CrossRef]

25. Coulina, M.; Cádiz-Gurrea, M.D.; Segura-Carretero, A. Extraction and Analysis of Phenolic Compounds in Rice: A Review. *Molecules 2018*, 23, 2890. [CrossRef]

26. Qi, Q.; Chu, M.; Yu, X.; Xie, Y.; Li, Y.; Du, Y.; Liu, X.; Zhang, Z.; Shi, J.; Yan, N. Anthocyanins and Proanthocyanidins: Chemical Structures, Food Sources, Bioactivities, and Product Development. *Food Res. Int.* 2022, 38, 1–29. [CrossRef]

27. Pattananandecha, T.; Apichai, S.; Sirilun, S.; Julsirigival, J.; Sawangrat, K.; Ogata, F.; Kawasaki, N.; Sirithunyalug, B.; Saenjum, C. Anthocyanin Profile, Antioxidant, Anti-Inflammatory, and Antimicrobial properties of black, red, and brown rice bran extracts. *IntechOpen: London, UK, 2019; pp. 1–16. [CrossRef]

28. Yazhen, S.; Wenju, W.; Panpan, Z.; Yuanyuan, Y.; Panpan, D.; Wusen, Z.; Yanling, W. Anthocyanins: Novel antioxidants in diseases prevention and human health. In *Flavonoids-A Coloring Model for Cheering Up Life*; IntechOpen: London, UK, 2019; pp. 1–29. [CrossRef]

29. Junmarkho, K.; Hansakul, P. Thai pigmented rice bran extracts inhibit production of superoxide, nitric oxide radicals and inducible nitric oxide synthase in cellular models. *Asian Pac. J. Trop. Biomed.* 2019, 9, 291. [CrossRef]

30. Saji, N.; Schwarz, L.J.; Santhakumar, A.B.; Blanchard, C.L. Stabilization treatment of rice bran alters phenolic content and antioxidant activity. *Cereal Chem.* 2020, 97, 281–292. [CrossRef]

31. Saji, N.; Francis, N.; Schwarz, L.J.; Blanchard, C.L.; Santhakumar, A.B. The Antioxidant and Anti-Inflammatory Properties of Rice Bran Phenolic Extracts. *Foods 2020*, 9, 829. [CrossRef]

32. Buxadé, M.; Huerca Encabo, H.; Riera-Borrull, M.; Quintana-Gallardo, L.; López-Cotarelo, P.; Tellechea, M.; Martínez-Martínez, S.; Redondo, J.M.; Martín-Caballero, J.; Flores, J.M.; et al. Macrophase-specific MHCII expression is regulated by a remote Ciita enhancer controlled by NFAT5. *J. Exp. Med.* 2018, 215, 2901–2918. [CrossRef]

33. Lee, A.; Ashkar, A. The dual nature of type I and type II interferons. *Front Immunol.* 2018, 9, 2061. [CrossRef]

34. Michlmayr, D.; McKimmie, C.S. Role of CXCL10 in central nervous system inflammation. *Int. J. Interferon Cytokine Mediat. Res.* 2014, 6, 1. [CrossRef]

35. Koga, R.S.; Rutledge, J.C.; Gohil, K.; Kumar, A.; Enelow, R.I.; Ramana, C.V. Regulation of gene expression in RAW 264.7 macrophage cell line by interferon-γ. *Biochem. Biophys. Res. Commun.* 2006, 342, 1137–1146. [CrossRef]

36. Rashighi, M.; Harris, J.E. Interfering with the IFN-γ/CXCL10 pathway to develop new targeted treatments for vitiligo. *Ann. Transl. Med.* 2015, 3, 343. [CrossRef]

37. Chan, E.D.; Riches, D.W. IFN-γ+ LPS induction of iNOS is modulated by ERK, JNK/SAPK, and p38 mapk in a mouse macrophage cell line. *Am. J. Physiol.-Cell Physiol.* 2001, 280, C441–C450. [CrossRef]
48. Chen, C.-W.; Chang, Y.-H.; Tsai, C.-J.; Lin, W.-W. Inhibition of IFN-γ-Mediated Inducible Nitric Oxide Synthase Induction by the Peroxisome Proliferator-Activated Receptor γ Agonist, 15-Deoxy-Δ12,14-Prostaglandin J2, Involves Inhibition of the Upstream Janus Kinase/STAT1 Signaling Pathway. *J. Immunol.* 2003, 171(1), 979. [CrossRef]

49. Blanchette, J.; Jaramillo, M.; Olivier, M. Signalling events involved in interferon-γ-inducible macrophage nitric oxide generation. *Immunology* 2003, 108, 513–522. [CrossRef]

50. Mishra, B.B.; Rathinam, V.A.K.; Martens, G.W.; Martinot, A.J.; Kornfeld, H.; Fitzgerald, K.A.; Sassetti, C.M. Nitric oxide controls the immunopathology of tuberculosis by inhibiting NLRP3 inflammasome–dependent processing of IL-1β. *Nat. Immunol.* 2013, 14, 52–60. [CrossRef]

51. Li, Y.; Wilson, H.L.; Kiss-Toth, E. Regulating STING in health and disease. *J. Inflamm.* 2017, 14, 11. [CrossRef]

52. de Oliveira Mann, C.C.; Orzalli, M.H.; King, D.S.; Kagan, J.C.; Lee, A.S.Y.; Kranzusch, P.J. Modular Architecture of the STING C-Terminal Tail Allows Interferon and NF-κB Signaling Adaptation. *Cell Rep.* 2019, 27, 1165–1175.e5. [CrossRef] [PubMed]

53. Hong, Z.; Ma, T.; Liu, X.; Wang, C. cGAS-STING pathway: Post-translational modifications and functions in sterile inflammatory diseases. *FEBS J.* 2021. [CrossRef] [PubMed]

54. Hopfner, K.-P.; Hornung, V. Molecular mechanisms and cellular functions of cGAS–STING signalling. *Nat. Rev. Mol. Cell Biol.* 2020, 21, 501–521. [CrossRef] [PubMed]

55. Tanaka, Y.; Chen, Z.J. STING specifies IRF3 phosphorylation by TBK1 in the cytosolic DNA signaling pathway. *Sci. Signal.* 2012, 5, ra20. [CrossRef] [PubMed]

56. Tarassishin, L.; Suh, H.-S.; Lee, S.C. Interferon regulatory factor 3 plays an anti-inflammatory role in microglia by activating the PI3K/Akt pathway. *J. Neuroinflammation* 2011, 8, 187. [CrossRef]

57. Abe, T.; Barber, G.N. Cytosolic-DNA-mediated, STING-dependent proinflammatory gene induction necessitates canonical NF-κB activation through TBK1. *J. Virol.* 2014, 88, 5328–5341. [CrossRef]

58. Cheng, Z.; Dai, T.; He, X.; Zhang, Z.; Xie, F.; Wang, S.; Zhang, L.; Zhou, F. The interactions between cGAS-STING pathway and pathogens. *Signal Transduct. Target. Ther.* 2020, 5, 91. [CrossRef]

59. Burdette, D.L.; Monroe, K.M.; Sotelo-Troha, K.; Iwig, J.S.; Eckert, B.; Hyodo, M.; Hayakawa, Y.; Vance, R.E. STING is a direct innate immune sensor of cyclic di-GMP. *Nature* 2011, 478, 515–518. [CrossRef]

60. Zhong, B.; Yang, Y.; Li, S.; Wang, Y.-Y.; Li, Y.; Diao, F.; Lei, C.; He, X.; Zhang, L.; Tien, P.; et al. The Adaptor Protein MITA Links Virus-Sensing Receptors to IRF3 Transcription Factor Activation. *Immunity* 2008, 29, 538–550. [CrossRef]

61. Iyer, S.S.; Cheng, G. Role of interleukin 10 transcriptional regulation in inflammation and autoimmune disease. *Crit. Rev. Immunol.* 2012, 32, 23–63. [CrossRef]

62. Benveniste, E.N.; Qin, H. Type I interferons as anti-inflammatory mediators. *Sci. STKE* 2007, 2007, pe70. [CrossRef] [PubMed]

63. Ahn, J.; Son, S.; Oliveira, S.C.; Barber, G.N. STING-dependent signaling underlies IL-10 controlled inflammatory colitis. *Cell Rep.* 2017, 21, 3873–3884. [CrossRef] [PubMed]

64. Johnson, B.M.; Uchimura, T.; Gallovic, M.D.; Thamilarasan, M.; Chou, W.-C.; Gibson, S.A.; Deng, M.; Tam, J.W.; Batty, C.J.; Williams, J. STING Agonist Mitigates Experimental Autoimmune Encephalomyelitis by Stimulating Type I IFN–Dependent and–Independent Immune-Regulatory Pathways. *J. Immunol.* 2021, 206, 2015–2028. [CrossRef] [PubMed]

65. Ouyang, W.; Rutz, S.; Crellin, N.K.; Valdez, P.A.; Hymowitz, S.G. Regulation and functions of the IL-10 family of cytokines in inflammation and disease. *Annu. Rev. Immunol.* 2011, 29, 71–109. [CrossRef]